PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
   Google Scholar   
Citation:
Annal Oncol vol 29 (suppl_8) Abstr LBA34
Meeting Instance:
ESMO 2018
Year:
2018
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3111  
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Exelixis  
Grants:
U10CA180821, U24CA196171  
Corr. Author:
 
Authors:
                                 
Networks:
LAPS-CT018, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-NY158, LAPS-UT003, NC002   
Study
Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: